Clinical Trial Update: Reveal® XT Performance Trial (XPECT) [Phase 4]

View source ↗

Summary

Phase 4 XPECT trial evaluating the Medtronic Reveal XT device for patients with atrial fibrillation and risk of cardiac arrhythmias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Cardiac Arrhythmias

Drugs mentioned

• Reveal XT

Snippet

Sponsor: Medtronic BRC | Conditions: Atrial Fibrillation, Risk of Cardiac Arrhythmias | Phase 4 | Status: COMPLETED